GlycoEra raises USD 130 Million Series B to advance targeted autoimmune therapies

28.05.2025 12:09, Rita Longobardi

GlycoEra secures major funding to accelerate clinical development of its precision degraders targeting IgG4—an antibody subtype increasingly recognized as a key driver in a range of autoimmune diseases.

The Swiss biotechnology company GlycoEra, ranked among the TOP 100 Swiss Startups, has raised USD 130 Million in an oversubscribed Series B round to advance its lead program GE8820 into clinical development. GE8820 is designed to selectively degrade IgG4, a subclass of antibodies linked to autoimmune diseases such as pemphigus, MuSK myasthenia gravis, and autoimmune encephalitis. The funds will also support pipeline expansion across other immunological indications.

The round was led by Novo Holdings, with new investors Catalio Capital Management, LifeArc Ventures, and the Qatar Investment Authority joining. Existing backers, including Sofinnova Partners, 5AM Ventures, Roche Ventures, and Bristol Myers Squibb, also participated, along with Agent Capital, MP Healthcare Venture Management, and Sixty Degree Capital.

GlycoEra's degraders are bispecific molecules produced via a one-step recombinant process. They target extracellular proteins with precision and durability, offering an alternative to traditional synthetic therapies. Preclinical data for GE8820 show sustained IgG4 depletion without broad immunosuppression.

In connection with the financing, Max Klement, Matthew Hobson (Catalio), and Sohaib Mir (LifeArc) have joined the board of directors.


Greg Fralish (Chief Business Officer), Tanmoy C. Ganguly (Chief Scientific Officer), and Ganesh V. Kaundinya (President & CEO)